GSK announces positive results from phase III trial of Nucala ...
GSK plc (LSE/NYSE: GSK) today announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive pulmonary disease (COPD).
MATINEE: Mepolizumab Significantly Reduces COPD …
Sep 9, 2024 · Mepolizumab was found to significantly reduce exacerbations in adults with chronic obstructive pulmonary disease (COPD), according to results from the MATINEE trial.
Mepolizumab Significantly Reduces COPD Exacerbations
Sep 12, 2024 · Findings showed a statistically significant and clinically meaningful reduction in the annualized rate of moderate to severe exacerbations with mepolizumab compared with placebo among patients treated for up to 104 weeks.
FDA Approves First Drug to Treat Group of Rare Blood Disorders in ...
Sep 25, 2020 · Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without...
Nucala | European Medicines Agency (EMA)
Nucala contains the active substance mepolizumab. How is Nucala used? Nucala can only be obtained with a prescription and should be prescribed by a doctor experienced in identifying and treating severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, HES or EGPA.
New add-on treatment for rare autoimmune inflammatory disorder
Sep 17, 2021 · EMA has recommended granting an extension of indication to Nucala (mepolizumab) as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA), a rare disorder that causes vasculitis (a chronic inflammation of small to medium-sized arteries and veins).
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment ...
2 hours ago · Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic ...
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
19 hours ago · News provided by DelveInsight Business Research, LLP Nov 12, 2024, 17:31 ET. Share this article. Share ... Mepolizumab is currently undergoing Phase III clinical trials for COPD, particularly in ...
Benralizumab versus Mepolizumab for Eosinophilic …
Feb 23, 2024 · We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab.
European Commission approves Nucala (mepolizumab) in three ... - GSK
Nov 17, 2021 · GlaxoSmithKline (GSK) plc today announced that the European Commission has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), for use in three additional eosinophil-driven diseases.